Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NKGen Biotech ( (NKGN) ) has issued an update.
On July 14, 2025, NKGen Biotech entered into a strategic collaboration agreement with HekaBio K.K. to develop, manufacture, and commercialize NKGen’s SNK01 autologous NK cell therapy in Japan and other agreed territories. HekaBio will lead regulatory activities and clinical trials in Japan, leveraging the country’s expedited regulatory environment for cell therapies. The agreement includes profit-sharing terms and a buy-out option for NKGen. This partnership aims to address significant health challenges in Japan’s aging population, particularly neurodegenerative diseases like Alzheimer’s and Parkinson’s.
More about NKGen Biotech
NKGen Biotech is a clinical-stage biotechnology company based in Santa Ana, California, focusing on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. The company is working on troculeucel, a novel NK cell therapy for neurodegenerative disorders and various cancers.
Average Trading Volume: 177,233
Technical Sentiment Signal: Sell
Current Market Cap: $12.59M
For an in-depth examination of NKGN stock, go to TipRanks’ Overview page.